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Summary We retrospectively reviewed our clinical experience with PGB when used
as add-on therapy in 101 patients (56 women and 45 men) with refractory partial
epilepsy, who have been followed up for at least 1 year. Mean age was 40 years
(16—64); mean number of concomitant AEDs was 2.8. Most patients (43) had temporal
lobe epilepsy. Median number of seizures per month was 16 (3—240). Mean PGB dose
used was 412.5 mg. Responder rate (percentage of patients with 50% seizure
reduction) at 6 and 12 months was 52% and 39.6%, respectively. Seizure freedom
for at least 6 and 12 months has been achieved by 12 patients (11.8%) and 6 patients
(5.9%) respectively. At 1 year, 61 patients (60.4%) are still taking PGB. Forty patients
have discontinued PGB, because of inefficacy (16 patients, 15.8%), adverse effects (15
patients, 14.8%) or both (9 patients, 8.9%). Sixty per cent of patients reported adverse
events, being weight gain (>10% body weight) the most frequent, seen in 26 patients
(25.7%). Dizziness/ataxia was seen in 20 (19.8%). Adverse effects were generally mild
to moderate.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Pregabalin is a new ligand for the alpha-2-delta
subunit associated with voltage-gated calcium
channels. Pregabalin has been shown to be effective
against seizures in a wide range of animal models,
has a linear pharmacokinetic profile, lack of protein
binding, lack of hepatic metabolism, and renal* Corresponding author. Tel.: +34 932275514;
fax: +34 932275783.
E-mail address: mcarreno@clinic.ub.es (M. Carren˜o).
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.05.011excretion. No drug—drug interactions have been
observed during clinical development.1 Data from
three pivotal studies2—4 indicate that PGB is highly
effective as adjunctive therapy in the treatment of
patients with partial seizures, with or without sec-
ondary generalization. The improvement rates in
these studies including highly refractory patients
ranged between 17.4% and 39.5%, with a good pro-
file of safety and tolerability.5 Most frequently
reported adverse events have been dizziness,
ataxia, weight gain, asthenia and somnolence. We
report our experience with PGB when used in every. Published by Elsevier Ltd. All rights reserved.
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with refractory epilepsy attending two Epilepsy
Units in tertiary hospitals.Patients and methods
We retrospectively identified epileptic patients
with persistent partial seizures in spite of treat-
ment with one, two or three antiepileptic drugs
(AEDs), who received PGB as add-on treatment and
were followed up for at least 1 year. The patients
attended the Epilepsy Clinics of two tertiary hospi-
tals, Hospital Clı´nic (Barcelona, Spain) and Hospital
Josep Trueta (Girona, Spain). We reviewed their
charts and analyzed type of epilepsy, number of
concomitant AEDs, seizure frequency before and
after 6 and 12 months of PGB, treatment emergent
adverse effects and retention rate at 12 months.
The analysis was performed on an intent-to-treat
basis.Figure 1 Retention rate on PGB shown in a survival
curve (follow-up: 1 year).Results
A total of 101 patients (56 women and 45 men)
received PGB as add-on treatment for refractory
partial epilepsy and have been followed up for at
least 1 year. Mean age was 40 years (16—64); mean
time from seizure onset was 22 years (7—53), mean
number of concomitant AEDs was 2.8. Eight patients
had history of recent status epilepticus or clusters of
seizures which prevented them from participating in
clinical trials.
All patients had focal epilepsy. Most patients had
temporal lobe epilepsy (43 patients), followed by
frontal lobe epilepsy (29 patients), unlocalized focal
epilepsy (23 patients), parieto-occipital epilepsy (4
patients) and multifocal epilepsy (2 patients). Sei-
zures were highly refractory, with a median number
of seizures per month of 16 (3—240).
Mean PGB dose reached was 412.5 mg (range
150—600). The titration scheme was similar in both
Epilepsy Units, with PGB started at a dose of 75 mg a
day, and then increased weekly by 75 mg until max-
imum tolerated dose or 600 mg.
Responder rate (percentage of patients with
50% seizure reduction) at 6 and 12 months fol-
low-up was 52% and 39.6%, respectively. Four
patients reported similar number of seizures but
less severity (shorter seizures or absence of general-
ized tonic clonic convulsions). Seizure freedom for
at least 6 and 12 months has been achieved by 12
(11.8%) and 6 (5.9%) patients, respectively. Increase
in seizure frequency, temporally related to the
drug, was seen in four patients (3.9%). PGB wasgenerally well tolerated. Sixty per cent of patients
reported at least one adverse effect, being weight
gain 10% body weight the most frequent, seen in
26 patients (25.7%). Weight gain was seen in 18/56
women and 8/45 men. Dizziness/ataxia was seen in
20 patients (19.8%). Dizziness/ataxia was especially
severe when PGB was added to regimens containing
PHT, CBZ or OXC. Dizziness/ataxia usually resolved
after lowering the dose of concomitant AEDs (by
30—50%), with no need to lower the total daily dose
of PGB.
Ten patients (9.9%) displayed lower limb oedema
not accompanied by ionic or other metabolic dis-
turbances, and four patients (3.9%) had dose-depen-
dent blurred vision. There were few cognitive
side effects, with only three patients reporting
psychomotor slowing. Unusual side effects included
enuresis (one patient) and impotence (one patient).
Adverse effects were generally mild to moderate in
severity. Only four patients had severe adverse
effects (weight gain leading to worse control of
concomitant diabetes mellitus, severe ataxia in
one patient who had concomitant treatment with
OXC which improved when lowering OXC dose,
severe increase in seizure frequency (100%) and
suicide attempt in one patient with a previously
known depression, which was not considered to
be drug related).
At 12 months, 61 patients continued taking PGB
(retention rate at 1 year: 60.4%) (Fig. 1). Forty
patients (39.6%) discontinued PGB, because of inef-
ficacy (16 patients, 15.8%), adverse effects (15
patients, 14.8%) or both (9 patients, 8.9%).Discussion
Our study confirms, under every day clinical prac-
tice conditions, previous data provided by con-
trolled studies about efficacy and tolerability of
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refractory partial seizures.
The responder rates observed at 6 and 12 months
(52% and 39.6%, respectively) observed in our popu-
lation of highly refractory epileptic patients is
encouraging, when considering that these patients
had a very high number of monthly seizures and
were treated with amean number of 2.8 other AEDs.
In a recent study,6 the responder rate was 31.3% for
a PGB flexible dose regimen which tried to repro-
duce routine clinical practice. It does not seem that
our strategy of decreasing dose of certain concomi-
tant AEDs decreases overall treatment efficacy; it
improves tolerability and, in our experience, it is
necessary in many patients to reach medium or high
PGB doses.
A particularly important fact in clinical practice
when treating refractory patients is the number of
patients who become seizure free with a new AED. In
fact, this is the goal for every patient and also for
the prescribing physician, with seizure freedom
being the most significant factor associated with
quality of life in epilepsy.7 According to several
authors, at least 6-month seizure free periods
should be provided for a meaningful estimation of
long term efficacy of AEDs.8,9 In our series, seizure
freedom for at least 6 and 12 months was achieved
by 12 (11.8%) and 6 (5.9%) patients, respectively,
which is similar to the percentages attained with
other new AEDs in patients with intractable epi-
lepsy.10 Retention rate at 1 year is also similar to
previously reported figures for LEV or TPM in similar
populations.11,12 Retention rate may be influenced
by factors independent from efficacy. In the absence
of significant adverse reactions, patients may con-
tinue on PGB even if seizure response was not
optimum, in the lack of a new alternative (ZNS
was not available in Spanish market until March
2006).
Adverse effects are always of concern in a popu-
lation of refractory patients, as polytherapy
increases significantly the risk of toxicity. In our
series, most side effects were mild to moderate
in intensity. Discontinuation rate because of adverse
effects was lower than in controlled studies, as
expected in daily clinical practice, but similar to
the flexible dose study.6 Experience acquired with
other AEDs led us to use a slower than recommended
titration rate. We feel that a starting dose of 75 mg a
day, with weekly increments of 75 mg, is adequate
and may be better tolerated, specially when treat-
ing patients who receive two or more concomitant
AEDs.
Weight gain was frequently seen. This adverse
effect has also been observed in controlled studies.
It may be appropriate to recommend a low caloriediet in patients who are prescribed PGB and to
control weight in every visit. Regarding lower limb
oedema, routine laboratory tests are normal in
these patients, and the oedema usually improves
when lowering PGB dose. Cognitive side effects,
which have a very negative impact in social and
laboral life of refractory epileptic patients, were
seen in few patients.
Limitations of our study include its retrospective
nature and the fact that the control data are histor-
ical rather than contemporary. However, we believe
it can provide useful information to the clinicians
given the size of the population studied and the
pattern of use of the drug, reflecting conditions of
actual clinical practice rather than the somewhat
artificial situation of a clinical trial.
In summary, PGB seems an effective and well
tolerated AED when used as add-on treatment in
patients with refractory partial epilepsy. When used
in every day clinical practice in highly refractory
patients, it may decrease seizure frequency by 50%
or more in up to 39% of patients at 1 year. Low
discontinuation rate due to adverse events was
seen, which is likely the result of slow titration,
lowering of concomitant AEDs and individual dose
adjustment.References
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